Bristol Myers Squibb (CELG-RI) FCF Margin Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) FCF Margin Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1,688.00 |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -1,334.00 |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1,096.00 |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -647.00 |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -158.00 |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1,388.00 |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3,383.00 |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1,020.00 |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 69.00 |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -518.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -518.00 |
| Mar 31, 2026 | -853.00 |
| Dec 31, 2025 | -2,007.00 |
| Sep 30, 2025 | 473.00 |
| Jun 30, 2025 | 1,207.00 |
| Mar 31, 2025 | -637.00 |
| Dec 31, 2024 | -127.00 |
| Sep 30, 2024 | 408.00 |
| Jun 30, 2024 | 241.00 |
| Mar 31, 2024 | -225.00 |
| Dec 31, 2023 | 822.00 |
| Sep 30, 2023 | 954.00 |
| Jun 30, 2023 | -223.00 |
| Mar 31, 2023 | -681.00 |
| Dec 31, 2022 | -523.00 |
| Sep 30, 2022 | -1,232.00 |
| Jun 30, 2022 | -762.00 |
| Mar 31, 2022 | -242.00 |
| Dec 31, 2021 | 342.00 |
| Sep 30, 2021 | 2,292.00 |